Evidence map›Paper›PMID 35056572›Full record

ArticleMicroorganisms2022

Microbial Secondary Metabolism and Biotechnology.

Mireille Fouillaud, Laurent Dufossé

Abstract read
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Microbial Metabolism: Primary and Secondary Metabolites.Progress in molecular and subcellular biology · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Labdane-Type Diterpenoids fromInternational journal of molecular sciences · 2024
    Article
  15. Article
  16. Frontiers in microbiology · 2024
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mireille FouillaudLaboratoire de Chimie et de Biotechnologie des Produits Naturels-CHEMBIOPRO, Université de la Réunion, 15 Avenue René Cassin, CS 92003, F-97744 Saint-Denis, Ile de la Réunion, France.ORCID 0000-0002-0562-2154
Laurent DufosséLaboratoire de Chimie et de Biotechnologie des Produits Naturels-CHEMBIOPRO, Université de la Réunion, 15 Avenue René Cassin, CS 92003, F-97744 Saint-Denis, Ile de la Réunion, France.ORCID 0000-0001-7392-355X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent decades scientific research has demonstrated that the microbial world is infinitely richer and more surprising than we could have imagined. Every day, new molecules produced by microorganisms are discovered, and their incredible diversity has not yet delivered all of its messages. The current challenge of research is to select from the wide variety of characterized microorganisms and compounds, those which could provide rapid answers to crucial questions about human or animal health or more generally relating to society's demands for medicine, pharmacology, nutrition or everyday well-being.

Indexed as

bioactive propertiesbiotechnologyextractionmicroorganismsperspectivesproductionscreeningsecondary metabolites

Identifiers

PMID35056572
PMCPMC8781746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.